biogen
Washington (AFP) - A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday. The US Food and Drug Administration awarded accelerated approval to Aduhelm in June 2021, a decision that was highly contentious at the time because the agency overruled its own independent advisors, who found there was insufficient evidence of benefit. At least three of the 11-member independent committee that voted unanimously against recommending the drug...
AFP
Washington (AFP) - Experts on Wednesday said they were encouraged after preliminary data for a new Alzheimer's drug showed it slowed cognitive decline, the first medicine to accomplish this goal. The treatment, called lecanemab, was tested in a clinical trial of nearly 1,800 people, and slowed cognitive decline by 27 percent across an 18-month period, according to early results announced by makers Biogen and Eisai. "This is the first drug that's been shown to not only remove the build-up of a protein called amyloid in the brain, but to have a small but statistically significant impact on cogni...
AFP
First on CNBC: CNBC Transcript: Biogen Inc (NASDAQ:BIIB) CEO Michel Vounatsos Speaks with CNBC’s “Power Lunch” today, discussing FDA’s approval of its Alzheimer’s drug. Q1 2021 hedge fund letters, conferences and more WHEN: Today, Monday, June 7 WHERE: CNBC’s “Power Lunch” Biogen CEO On FDA Approval For Its Alzheimer’s DrugAll references must be sourced to CNBC. MEG TIRRELL: Kelly, thanks so much. Michel Vounatsos joins us now, the news of the week, the year, this is huge. Michel, the first Alzheimer’s drug approved in 18 years. The first ever to potentially slow the course of the disease but ...
ValueWalk
Del Principe O’Brien Financial Advisors commentary for the month ended March 2021, discussing their portfolio holdings and their recent investment in Biogen Inc (NASDAQ:BIIB). Q1 2021 hedge fund letters, conferences and more Dear Fellow Investors, “There's nothing particularly earth-shattering about what we try to do. We believe the market often misprices stocks due to neglect, emotion, misinterpretation or myopia, so our value-add comes from bottom-up stock selection. We're trying to buy at low prices relative to our current estimate of intrinsic value and we want to believe that intrinsic va...
ValueWalk
Fairpointe Mid-Cap Composite commentary for the fourth quarter ended December 31, 2021. Q4 2020 hedge fund letters, conferences and more We See Benefits from Continued Market RotationThe trends in market rotation that we discussed recently have continued and have been positive for our stocks. After several years of markets being dominated by growth, momentum, and passive investing, we have seen a reset back to fundamental value-based investing. The pandemic in 2020 resulted in disruption to growth in economies around the world. With the availability of vaccines, attractively valued companies t...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら